Related Experiment Videos
[Clinical features and treatment results in 88 children with malignant lymphoma]
Insights
This study reports on 88 children with malignant lymphoma, finding that treatment combining radiotherapy, chemotherapy, or surgery yields the best outcomes. Prognostic factors include stage, type, age, treatment, remission, and radiation dose for pediatric lymphoma patients.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Research
Context:
- Malignant lymphoma in children presents diagnostic and therapeutic challenges.
- A significant misdiagnosis rate (90%) was observed in the studied pediatric population.
- Treatment modalities varied, including radiotherapy, chemotherapy, and surgery.
Purpose:
- To analyze clinical features and treatment outcomes for 88 children diagnosed with malignant lymphoma between 1973 and 1984.
- To identify key prognostic factors influencing survival rates in pediatric lymphoma.
- To evaluate the efficacy of different treatment regimens.
Summary:
- The study included 39 cases of Hodgkin's disease and 41 of non-Hodgkin's lymphoma.
- Complete remission (CR) was achieved in 40.7% and partial remission (PR) in 42.8% of patients.
- Radiotherapy combined with chemotherapy or surgery resulted in the highest CR rate (60.8%) and improved survival.
Impact:
- Overall 3 and 5-year survival rates were 51.4% and 46%, respectively.
- Survival rates were significantly higher for Hodgkin's disease compared to non-Hodgkin's lymphoma.
- Favorable prognostic indicators identified include early stage, specific pathologic types, age, combined treatment modalities, complete remission, and optimal radiation dosage (4,100-5,200 rad).
Abstract:
Clinical features and treatment results of 88 children with malignant lymphoma as treated in our hospital from Jan. 1973 to May 1984 are reported. These patients were 39 Hodgkin's disease, 41 non-Hodgkin's lymphoma and 8 unclassified. Peak age ranged from 6 to 10 years. 12 patients were in stage I, 35 in stage II, 7 in stage III and 34 in stage IV. In this series, misdiagnosis rate was 90%. The treatment methods included radiotherapy plus chemotherapy or surgery and chemotherapy alone. The complete remission rate (CR) was 40.7% and partial remission (PR) 42.8%. The radiotherapy plus chemotherapy or surgery gave the highest CR (60.8%). The overall 3 and 5 year survival rates were 51.4% and 46%. In stages I and II, 5 year survival rate was 67.6% and in stages III and IV, it was 15%. The 3 and 5 year survival rates in CR were 87% and 75%, that in PR were 18.2% and 12.1%. Those of Hodgkin's disease were higher than that of non-Hodgkin's lymphoma (92.5% and 75% versus 25.8% and 19.3%). The 5 year survival of radiotherapy plus chemotherapy or surgery was the highest. The patients who received a tumor dose of 4,100-5,200 rad had the best prognosis (81% for 5 year survival rate). It is indicated that the stage, pathologic type, age, treatment method, CR and radiation dose are the prognostic factors in children with malignant lymphoma.